From the Journals

Should SGLT-2 Inhibitors Be Continued After a UTI?

Patients with type 2 diabetes who developed urinary tract infections while taking sodium-glucose cotransporter-2 inhibitors faced higher heart and kidney risks.

Share

11 Key Takeaways

  • 1

    Stopping SGLT-2 inhibitors after UTI may increase mortality risk.

  • 2

    Study involved 61,606 adults with type 2 diabetes.

  • 3

    UTI incidence was

  • 4

    36%;

  • 5

    39% severe.

  • 6

    Patients with UTIs faced increased cardiovascular and renal risks.

  • 7

    3

  • 8

    31% discontinued SGLT-2 inhibitors post-UTI.

  • 9

    Discontinuation did not reduce UTI recurrence.

  • 10

    Risks of adverse outcomes rise significantly after discontinuation.

  • 11

    Study suggests reevaluating treatment strategies involving SGLT-2 inhibitors.

Original Source(s)

Should SGLT-2 Inhibitors Be Continued After a UTI?

Patients with type 2 diabetes who developed urinary tract infections while taking sodium-glucose cotransporter-2 inhibitors faced higher heart and kidney risks.

  • by Kathryn Wighton

  • November 4, 2025

  • 3 min

Related Content

Plozasiran Wins FDA Nod for FCS

Arrowhead’s small interfering RNA therapy reduced triglycerides and lowered pancreatitis risk in the phase 3 PALISADE trial, providing a quarterly self-administered option for patients with familial chylomicronemia syndrome.

Waist Circumference Link to DR

Obesity measure linked to diabetic retinopathy risk in US adults

Testing Metformin’s Reach in PAD

Double-blind trial of 202 patients shows no improvement in 6-minute walk distance at 6 months compared with placebo.